VIDEO: Oculis highlights pipeline of eye drop treatments
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Oculis CEO Riad Sherif, MD, provides a status report on OCS-01, OCS-02 and OCS-05 eye drops.
OCS-01 would be the first topical treatment for diabetic macular edema if approved by the FDA, according to Sherif. OCS-02 is a TNF alpha blocker for inflammation with indications in dry eye disease and uveitis, while OCS-05 is an SGK-2 activator designed to treat acute optic neuritis.
“If this product works in acute optic neuritis, it really opens the door for multiple clinical applications for neuroprotection such as glaucoma, diabetic retinopathy and [geographic atrophy] on top of neurotrophic keratitis, which is another indication we are exploring with this new molecular entity,” he said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts